Only 12 high-income countries are on track to meet the World Health Organization’s goal of eliminating hepatitis C as a public health threat by 2030, and micro-elimination opportunities in high-risk populations in settings such as hospitals are often overlooked. We propose ten steps to eliminate hepatitis C in hospitals.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Gamkrelidze, I. et al. Progress towards hepatitis C virus elimination in high-income countries: an updated analysis. Liver. Int. 41, 456–463 (2021).
Lazarus, J. V. et al. A global systematic review of hepatitis C elimination efforts through micro-elimination. Semin. Liver Dis. https://doi.org/10.1055/a-1777-6112 (2022).
Lazarus, J. V. et al. A cascade of care analysis on the elimination of hepatitis C from public hospitals in Madrid. Commun. Med. 2, 20 (2022).
Casas, M. P. et al. Towards the elimination of hepatitis C: implementation of reflex testing in Andalusia. Rev. Esp. Enferm. Dig. 112, 515–519 (2020).
Marcellusi, A. et al. Optimizing diagnostic algorithms to advance Hepatitis C elimination in Italy: a cost effectiveness evaluation. Liver Int. 42, 26–37 (2022).
Lazarus, J. V. et al. We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade. J. Intern. Med. 286, 503–525 (2019).
Aleman, S., Söderholm, J., Büsch, K., Kövamees, J. & Duberg, A.-S. Frequent loss to follow-up after diagnosis of hepatitis C virus infection: a barrier towards the elimination of hepatitis C virus. Liver Int. 40, 1832–1840 (2020).
European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: final update of the series. J. Hepatol. 73, 1170–1218 (2020).
Crespo, J. et al. Eliminación de la hepatitis C. Documento de posicionamiento de la Asociación Española para el Estudio del Hígado (AEEH) [Spanish]. Gastroenterol. Hepatol. 42, 579–592 (2019).
Saludes, V. et al. Evaluation of the Xpert HCV VL Fingerstick point-of-care assay and dried blood spot HCV-RNA testing as simplified diagnostic strategies among people who inject drugs in Catalonia, Spain. Int. J. Drug Policy. 80, 102734 (2020).
Acknowledgements
J.V.L. acknowledges support to ISGlobal from the Spanish Ministry of Science, Innovation and Universities through the “Centro de Excelencia Severo Ochoa 2019–2023” Programme (CEX2018-000806-S) and from the Government of Catalonia through the CERCA Programme. The Spanish Association for the Study of the Liver (AEEH; of whom J.L.C., M.B., J.C., F.J. and J.V.L. are members) received financial support from AbbVie to convene the authors in the preparation of Box 1. The authors were not remunerated for writing this Comment.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.L.C. reports grants to his institution from Gilead Sciences and personal fees from AbbVie, Gilead Sciences, MSD and Intercept, outside of the submitted work. A.A. reports personal fees from AbbVie, Gilead Sciences, MSD, Roche and Abbott, outside of the submitted work. M.B. reports advisory fees from Gilead Sciences, AbbVie, GlaxoSmithKline and Assembly Biosciences, and speaker fees from Gilead Sciences and AbbVie, outside of the submitted work. J.C. reports consulting and personal fees from Gilead Sciences, AbbVie, MSD, Shionogi, Intercept Pharmaceuticals, Janssen Pharmaceuticals Inc., Celgene and Alexion, outside of the submitted work. F.G. reports grants to his institution from AbbVie, Gilead Sciences, MSD and ViiV, and personal fees from AbbVie, Gilead Sciences, Janssen, MSD, ViiV, Roche, Qiagen and Menarini, outside of the submitted work. L.E.M. reports personal fees from AbbVie, Gilead Sciences, Janssen, MSD and ViiV, outside of the submitted work. J.M. reports grants to his institution from Gilead Sciences, MSD, Janssen and ViiV, and personal fees from Gilead Sciences, MSD and ViiV, outside of the submitted work. J.V.L. reports grants to his institution from AbbVie, Gilead Sciences and MSD, and personal fees from AbbVie, CEPHEID, Gilead Sciences, GSK, Genfit, Intercept, Janssen, MSD and ViiV, outside of the submitted work. F.J. declares no competing interests.
Rights and permissions
About this article
Cite this article
Calleja, J.L., Aguilera, A., Buti, M. et al. Ten steps to eliminating hepatitis C in hospitals. Nat Rev Gastroenterol Hepatol 19, 481–483 (2022). https://doi.org/10.1038/s41575-022-00647-1
Published:
Issue date:
DOI: https://doi.org/10.1038/s41575-022-00647-1
This article is cited by
-
The path to successful hepatitis C elimination in Spain
Nature Reviews Gastroenterology & Hepatology (2023)
